10-Q: Intelligent Bio Solutions Reports Revenue Growth Amidst Going Concern Doubts

Intelligent Bio Solutions Inc. reported record quarterly revenue and improved gross profit, but faces substantial doubt about its ability to continue as a going concern and delays in FDA clearance.

Summary

• Intelligent Bio Solutions Inc. (INBS) reported record quarterly revenue of $1,111,797 for the three months ended September 30, 2025, a 28% increase compared to $872,287 in the prior year quarter.
• Gross profit increased by 49.4% to $518,291, with the gross profit margin improving to 46.6% from 39.68% in the same period last year, driven by a shift to higher-margin products and enhanced production efficiency.
• Net loss attributable to Intelligent Bio Solutions Inc. increased to $(2,983,006) for the quarter, compared to $(2,685,633) in the prior year, despite a decrease in net loss per share to $(0.35) from $(0.70) due to a higher weighted average share count.
• The company's cash and cash equivalents stood at $1,660,105 as of September 30, 2025, with a working capital deficit of $(577,705).
• Management believes current cash will be insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Development and regulatory approval expenses decreased by 48.76% to $486,169, primarily due to the timing of research partner engagement.
• Selling, general and administrative expenses increased by 36.47% to $2,659,824, mainly due to increased marketing, promotion, legal, and repair costs.
• An impairment loss of $261,780 was recorded for long-lived assets held for sale during the quarter.
• The company secured a major contract with a large London public transport operator, spanning 14 sites and over 4,400 staff.
• A new global distribution agreement was signed with SMARTOX for the SmarTest Patch drug detection product in international markets outside the U.S. and Canada.
• 33 new customer accounts were added during the quarter, bringing the total active accounts to 492.

Sentiment

Score: 3

Explanation: While revenue growth and gross profit improvement are positive, the explicit 'going concern' warning, increased net loss, significant cash burn from operations, material weaknesses in internal controls, and delays in key product approvals create a highly negative outlook. The capital raises are necessary but highlight ongoing financial instability.

Positives

• Record quarterly revenue of $1,111,797, representing a 28% increase year-over-year and 32% growth from the previous quarter.
• Gross profit increased by 49.4% to $518,291, with the gross profit margin improving to 46.6% from 39.68% due to a favorable product mix and production efficiency.
• Cartridge sales, which are repetitive by nature, accounted for 57.59% of total sales, up from 51.14% in the prior year.
• Secured a major contract with a large London public transport operator, covering 14 operational sites and over 4,400 staff.
• Established a new global distribution agreement with SMARTOX for the SmarTest Patch in international markets.
• Expanded product portfolio with the addition of the SmarTest Patch, an innovative wearable device for continuous drug detection.
• Added 33 new customer accounts, increasing the total active accounts to 492.
• Working capital deficit improved to $(577,705) from $(1,212,419) as of June 30, 2025.

Negatives

• Net loss attributable to Intelligent Bio Solutions Inc. increased to $(2,983,006) for the quarter, compared to $(2,685,633) in the prior year.
• Selling, general and administrative expenses increased significantly by $710,808 to $2,659,824, primarily due to higher marketing, promotion, legal, and repair costs.
• Incurred an impairment loss of $261,780 on long-lived assets held for sale.
• Net cash used in operating activities increased to $(2,846,825) from $(2,387,216) in the prior year, indicating increased cash burn.
• Interest income decreased by $44,336 to $8,504 due to the spending of funds from capital raising activities.
• Material weaknesses were identified in internal control over financial reporting, specifically in control environment, risk assessment, control activities, information and communication, and monitoring.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months without raising additional funds.
• Inability to raise additional capital on favorable terms, or at all, could force delays or reductions in research programs, limit or cease operations, or lead to asset sales.
• Potential delisting from the Nasdaq Capital Market if the company fails to comply with listing requirements, including the minimum bid price (currently $0.7845 as of November 10, 2025).
• Extended delays in FDA 510(k) clearance for the Intelligent Fingerprinting Drug Screening System, with a new submission required and anticipated clearance in the second half of calendar year 2026.
• Impact of U.S. government shutdowns on FDA and SEC operations, potentially delaying product approvals or SEC filings.
• Extended delays or unfavorable terms in negotiating licensing of the Biosensor IP with the University of Newcastle due to the ongoing liquidation of Life Science Biosensor Diagnostics Pty Ltd (LSBD).
• Risk of being unable to repay a $2,172,108 grant to the Australian Government when due, which could result in defaults and enforcement actions.
• Loss of 'emerging growth company' status at the end of the current fiscal year (June 30, 2026) will increase reporting and compliance obligations.
• Material weaknesses in internal control over financial reporting could expose the company to regulatory scrutiny or sanctions and harm its reputation and stock price.

Future Outlook

The company anticipates operating losses for the foreseeable future and does not expect to generate positive cash flows from operating activities until it achieves regulatory approval in the U.S. and other markets, expands its revenue base, and continues product development. Development and regulatory expenses are expected to increase as the company gathers additional data for its new FDA 510(k) submission. Selling, general, and administrative expenses are also anticipated to rise with expansion into new regions. The company plans to continue improving its strategic sales mix and operational streamlining to drive increased gross profit and cost efficiency. Further development of the Biosensor Platform Technology (BPT) is postponed until appropriate licensing arrangements can be finalized with the University of Newcastle.

Management Comments

• "We expect this trend [revenue increase] to continue as we expand into new markets in the future."
• "We plan to continue to improve on our strategic sales mix and operational streamlining thus driving the increased gross profit as noted above."
• "We anticipate these costs [SG&A] will increase as we continue to expand in new regions."
• "We aim to increase our cost efficiency as we streamline the business and implement changes, delivering increased value for investors."
• "We expect development and regulatory expenses to increase in future periods as the Company continues to work to gather additional supporting data to strengthen its new 510(k) submission to the FDA."
• "Management believes there is a material risk that the Companys cash and cash equivalents as of September 30, 2025, of approximately $1.66 million, will be insufficient to fund its current operating plan through at least the next twelve months from the issuance of these unaudited condensed consolidated financial statements."
• "Accordingly, the Company will be required to raise additional funds during the next 12 months."
• "These conditions raise substantial doubt about the Companys ability to continue as a going concern unless it can successfully meet the stated objectives and/or raise additional capital."

Industry Context

Intelligent Bio Solutions operates in the medical technology sector, focusing on rapid, non-invasive testing and screening solutions. Its primary product, the Intelligent Fingerprinting Platform, targets drug screening in safety-critical industries, rehabilitation, and judicial organizations. The company is actively expanding its market share in the UK, mainland Europe, and the Asia Pacific Region, and is working towards FDA clearance in the U.S. The addition of the SmarTest Patch and new distribution agreements indicate a strategy to broaden its product offerings and global reach within the drug testing market. The industry is characterized by rapid change and intense competition, requiring continuous innovation and regulatory navigation.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. The focus is on internal financial performance and operational updates.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently engaged in any material legal proceedings that it believes could reasonably be expected to have a material adverse effect on its financial condition, results of operations or liquidity.

Related Party Transactions

• The company entered into an Investor Relations and Corporate Development Advisory Agreement with ClearThink Capital LLC on February 29, 2024, for which it pays a monthly cash fee of $5,000 and issues restricted common stock with a value of $4,000 per month. For the three months ended September 30, 2025, $12,000 of expense was recognized, and 8,164 shares of restricted stock were issued to ClearThink.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises and warrant exercises. The 'going concern' warning and Nasdaq delisting risk pose substantial threats to investment value. Material weaknesses in internal controls could erode confidence.
• **Employees:** Potential impact on job security if the company is unable to raise sufficient funding and is forced to delay or reduce operations. The increase in shares for the incentive plan could be a positive for retention.
• **Customers:** Continued product development and market expansion (e.g., London transport contract, SMARTOX distribution) suggest improved access to products and services. However, delays in FDA approval could impact product availability in the U.S.
• **Suppliers:** The company relies on various suppliers, with the largest accounting for 17.6% of purchases. The company's liquidity issues could pose a risk to timely payments to suppliers.
• **Creditors:** The 'going concern' warning and the $2,172,108 payable to the Australian Government highlight increased credit risk. Failure to raise capital could impair the ability to meet obligations.

Next Steps

• Raise additional funds during the next 12 months to meet working capital requirements and fund operations.
• Continue to work to gather additional supporting data to strengthen the new 510(k) submission to the FDA for the Intelligent Fingerprinting Drug Screening System.
• Finalize appropriate licensing arrangements related to the Biosensor Platform Technology (BPT) with the University of Newcastle to resume its development.
• Continue implementing new accounting systems for subsidiaries to enhance internal controls.
• Add accounting and finance personnel to improve segregation of duties and oversight in financial reporting.
• Enhance controls for complex accounting measurements and financial statement disclosures.
• Engage outside consultants to assist in evaluating and documenting internal controls.
• Monitor and address compliance with Nasdaq Capital Market listing requirements to avoid delisting.

Key Dates

Recommendation

Despite some positive operational developments like revenue growth and new contracts, the filing presents critical red flags that warrant a 'strong sell' recommendation. The explicit 'substantial doubt about its ability to continue as a going concern' is the most severe warning, indicating a high risk of insolvency without immediate and significant capital infusion. The company's cash position is deemed insufficient for the next 12 months, and it continues to burn cash from operations. Furthermore, the identified material weaknesses in internal control over financial reporting raise serious concerns about the reliability of financial statements and operational integrity. Delays in FDA approval for key products and unresolved intellectual property licensing issues for the Biosensor Platform add to the uncertainty. The stock is already trading below Nasdaq's minimum bid price, signaling market distress and increasing delisting risk. While capital raises have occurred, they are dilutive and merely address short-term liquidity without resolving the fundamental going concern issue. The cumulative risks far outweigh the operational positives, making the stock a high-risk investment with significant downside potential.

Keywords

Medical Technology, Drug Screening, Fingerprint Sweat Testing, FDA 510(k), Biosensor, Point-of-Care Testing, Liquidity, Going Concern, Capital Raise, Nasdaq Delisting Risk, Internal Controls, SEC Filing, Quarterly Report